Last updated: May 15, 2023
Sponsor: Regionshospitalet Silkeborg
Overall Status: Active - Recruiting
Phase
4
Condition
Musculoskeletal Diseases
Dupuytren's Disease
Connective Tissue Diseases
Treatment
Percutaneous needle fasciotomy
Saline injection
Corticosteroid injection
Clinical Study ID
NCT05440240
2022-985
2022-501021-20-00
Ages 45-99 All Genders
Study Summary
Eligibility Criteria
Inclusion
Sufficient correction of metacarpophalangeal (MCP) joint during the PNF treatment, definedas <20° passive extension deficit (PED), is a prerequisite for inclusion. Inclusion Criteria:
- Dupuytren contracture (DC) of ≥ 20° PED in MCP joint measured with a goniometer
- DC of either II-V finger
- Well-defined/palpable cord
Exclusion
Exclusion Criteria:
- Legally incapacitated
- Previous study inclusion with another finger ray
- Isolated proximal interphalangeal (PIP) or distal interphalangeal (DIP) jointcontracture, defined as MCP joint contracture < 20° PED regardless of the deficit inthe PIP or DIP joint
- Previous hand surgery of the affected finger for any reason
- Known allergy to the study medication
- Anticoagulant therapy (Acetylsalicylic acid is NOT an exclusion criterion)
- Pregnant or lactation
- Insulin dependent diabetes mellitus
- Ongoing systemic infection or local infection at the site of the procedure
- Rheumatoid arthritis
- Amyloidosis or mucopolysaccharidosis
- Unable to communicate, cooperate or participate in follow-up
Study Design
Total Participants: 400
Treatment Group(s): 3
Primary Treatment: Percutaneous needle fasciotomy
Phase: 4
Study Start date:
January 10, 2023
Estimated Completion Date:
March 31, 2030
Connect with a study center
Silkeborg Regional Hospital
Silkeborg, 8600
DenmarkActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.